[1] 赖荣陶,于乐成,陈成伟.2021 药物性肝损伤研究回顾和临床关注的问题[J].肝脏,2022,27(1):1-3. [2] Wang TL,Zhao XY,Shao C,et al. A proposed pathologic sub -classification of drug-induced liver injury[ J]. Hepatol Int,2019,13(3):339-351. [3] 于乐成,刘鸿凌,赵新颜 ,等.2021 版《ACG临床指南:特异质性药物性肝损伤的诊断和处理》 精粹介绍及相关思考[J].肝脏,2021,26(5) :465-476. [4] 杨燕,葛斐林,黄倩,等.中药相关肝损伤的风险因素[J].临床肝胆病杂志,2022,38(5):1183-1187. [5] 付丽红,高月求,王晓琳,等.38例药物性肝损伤患者肝组织病理学特征分析[J].实用肝脏病杂志,2022,25(4):512-516. [6] Murray M,Fisher. Mechanisms of drug-induced cholestasis[J]. Methods Mol Biol,2019,1981:151-156. [7] Burban A,Sharanek A,Hüe R,et al. Penicillinase resistant antibiotics induce non-immunemediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways[J]. Sci Rep,2017,7(1):1815. [8] Zoubek ME,González-Jimenez A,Medina-Cáliz I, et al. High prevalence of ibuprofen drug-induced liver injury in Spanish and Latin-American Registries[J]. Clin Gastro-enterol Hepatol,2018,16(2):292-294. [9] Velayudham LS,Farrell GC. Drug-induced cholestasis[J]. Expert Opin Drug Saf,2003,2(3):287-304. [10] Shen T,Huang X,Wang YY,et al. Current status of epidemiological studies on drug -induced liver injury in China[J]. J Clin Hepatol,2018, 34(6):1152 -1155. (in Chinese) [11] 许艺凡,邢卉春.药物性肝损伤诊断与治疗研究进展[J].药物不良反应杂志, 2022,24(5):258-263. [12] Medina-Caliz I,Robles-Diaz M,Garcia-Muñoz B,et al. Definition and risk factors for chronicity following acute idiosyncratic drug -induced liver injury[J]. J Hepatol,2016,65(3):532 - 542. [13] Erlinger S. Drug-induced cholestasis[J]. Hepatol,1997,26(Suppl.1):1-4. [14] 周金.糖皮质激素治疗高胆红素血症伴急性药物性肝损伤的临床疗效及其对肝功能指标的影响[J].临床合理用药杂志,2021,14(30):114-116. [15] 叶立红,王翀奎,邵晨,等.胆管细胞损伤型药物性肝损伤病理与临床生化特征分析[J].临床肝胆病杂志,2020,36(5):1059-1064. |